Could a constipation drug slow cancer growth? new trial seeks answers
NCT ID NCT07354919
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if axelopran, a drug used for opioid-induced constipation, can slow tumor growth in people with advanced breast, lung, pancreas, or prostate cancer. About 34 adults whose cancer has worsened after standard treatment will take axelopran daily for up to a year. Researchers will check tumor response at 6 weeks and monitor safety and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
HealthPartners Cancer Center at Regions Hospital
RECRUITINGSaint Paul, Minnesota, 55101, United States
-
HealthPartners Frauenshuh Cancer Research Center
RECRUITINGSaint Louis Park, Minnesota, 55426, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a new tracer light up hidden prostate cancer?
- Phone-Based navigation could boost breast cancer detection in kenya
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts